Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Gains from Investment Securities: 2014-2025

Historic Gains from Investment Securities for Iovance Biotherapeutics (IOVA) over the last 6 years, with Sep 2025 value amounting to $466,000.

  • Iovance Biotherapeutics' Gains from Investment Securities fell 92.58% to $466,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year decrease of 38.39%. This contributed to the annual value of $12.9 million for FY2024, which is 360.04% up from last year.
  • As of Q3 2025, Iovance Biotherapeutics' Gains from Investment Securities stood at $466,000, which was down 7.54% from $504,000 recorded in Q2 2025.
  • Over the past 5 years, Iovance Biotherapeutics' Gains from Investment Securities peaked at $6.3 million during Q3 2024, and registered a low of $177,000 during Q2 2023.
  • In the last 3 years, Iovance Biotherapeutics' Gains from Investment Securities had a median value of $880,000 in 2024 and averaged $2.0 million.
  • In the last 5 years, Iovance Biotherapeutics' Gains from Investment Securities soared by 1,556.20% in 2024 and then plummeted by 92.58% in 2025.
  • Quarterly analysis of 3 years shows Iovance Biotherapeutics' Gains from Investment Securities stood at $186,000 in 2023, then soared by 373.12% to $880,000 in 2024, then tumbled by 92.58% to $466,000 in 2025.
  • Its Gains from Investment Securities was $466,000 in Q3 2025, compared to $504,000 in Q2 2025 and $5.6 million in Q1 2025.